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582Objective: Extracorporeal membrane oxygenation remains the mainstay of mechanical circulatory support
initiation and maintenance in children with cardiac insufficiency. However, the outcomes after prolonged extra-
corporeal membrane oxygenation for cardiac insufficiency in children remain ill defined.
Methods:We reviewed the International Extracorporeal Life Support Organization data from January 1, 2000,
through December 31, 2011. We defined prolonged extracorporeal membrane oxygenation as uninterrupted
support for 14 days.
Results:A total of 777 children aged<18 years required extracorporeal membrane oxygenation support for14
days. Of these, 176 (23%) survived to hospital discharge. Compared with the nonsurvivors, the survivors were
older (median age, 0.64 vs 0.10 years; P<.01), weighed more (median weight, 7.0 kg; range, 2-90; vs median,
4.0; range, 1.4-100 kg; P<.01), had a shorter duration of support (mean, 20 6 vs 22 9 days; P<.01), and a
fewer number of organ system complications (mean, 2.8  1.7 vs 3.6  1.6, P<.01). Children with congenital
heart disease had worse survival than those with cardiomyopathy and myocarditis (15% vs 42% and 52%,
respectively; P<.01), and thosewith 1-ventricle physiology had worse survival than thosewith 2-ventricle phys-
iology (10% vs 18%, P ¼ .01). Seven percent (n ¼ 56) reached cardiac transplantation, with 66% surviving to
hospital discharge versus 19% of those not transplanted (P<.01).
Conclusions: The attrition is high after prolonged extracorporeal membrane oxygenation support for cardiac
insufficiency in children. Cardiac transplantation in this cohort was rarely achieved and was associated with
high mortality compared with benchmarks for cardiac transplantation survival. Earlier redirection of care or
conversion to other modes of mechanical support as a bridge to transplantation should be considered. (J Thorac
Cardiovasc Surg 2014;148:582-8)Despite recent advances in pediatric ventricular assist de-
vice (VAD) technology and approval by Food and Drug
Administration, this form of circulatory support is not
widely available and cannot always be implemented in
emergent situations. Hence, extracorporeal membrane
oxygenation (ECMO) remains the mainstay of mechanical
circulatory support initiation and maintenance for cardiac
insufficiency in children.1,2 The goal of ECMO is to
provide organ perfusion while allowing the heart to
recover or to provide support pending cardiac
transplantation. Single and multicenter studies have
reported high mortality after ECMO for cardiac
insufficiency in children.3-8e University of Missouri Kansas City School of Medicine,a Kansas
Mo; and Heart Center,b Children’s Mercy Hospital, Kansas City, Mo.
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The Journal of Thoracic and Cardiovascular SurgScant reports have been published regarding the out-
comes after prolonged cardiac ECMO for cardiac disease
in children. A small study considered the outcomes after
ECMO support of 28 days and found that only 3 of 22
children had survived and had chronic morbidities.9 A
single-center study from the 1990s of 34 children reported
that most recovery had occurred in the first week of
ECMO support and that those needing a longer duration
of support did not survive unless they had undergone heart
transplantion.10 A recent report linked the Organ Procure-
ment and Transplant Network database with the Extracor-
poreal Life Support Organization (ELSO) database during
a 15-year period identifying any child aged <18 years
whowas supported by ECMO and listed for heart transplan-
tation. Those who received ECMO support for>14 days
and were subsequently transplanted had poor survival; how-
ever, that study did not consider the outcomes of all children
after prolonged cardiac ECMO, irrespective of their listing
status.11
ECMO has at times been continued indefinitely in antic-
ipation of cardiac recovery, whether or not the center offers
cardiac transplantation or other forms of mechanical circu-
latory support. Transport with the patient receiving ECMOery c August 2014
Abbreviations and Acronyms
ECMO ¼ extracorporeal membrane oxygenation
ELSO ¼ Extracorporeal Life Support Organization
VAD ¼ ventricular assist device
Merrill et al Congenital Heart Diseaseto centers offering heart transplantation or other forms of
mechanical circulatory support will be challenging for
many centers. We undertook the present investigation of
children aged<18 years who require prolonged ECMO
for cardiac disease, because the outcomes for this cohort
are largely unknown. The principal aims were to identify
the characteristics of children with cardiac insufficiency,
for whom prolonged ECMO might serve as a bridge to re-
covery or heart transplantation.C
H
DMETHODS
The ELSO registry is a multicenter, international registry that collects
detailed clinical information on children supported with ECMO, including
adverse events, using standardized definitions. We conducted a retrospec-
tive review of the ELSO database to include children aged<18 years
who were receiving ECMO for cardiac support from January 1, 2000, to
December 31, 2011 (12 years). The inclusion criteria for the present study
were children aged<18 years receiving ECMO for cardiac insufficiency
for an uninterrupted duration of 14 days (prolonged cardiac ECMO).
The institutional review board at Children’s Mercy Hospital approved the
study as an exempt study.
Data collection included age and weight at ECMO initiation, gender,
race, year of ECMO, and number of ECMO days. The cardiac diagnostic
category was derived from the International Classification of Diseases,
version 9, codes, Current Procedural Terminology codes, and ELSO diag-
nostic codes that were entered by the individual centers into the ELSO reg-
istry. These were grouped as follows: congenital heart disease, which was
further divided into 1-ventricle and 2-ventricle physiology, cardiomyopa-
thy, myocarditis, and other, which included shock, pulmonary hyperten-
sion, and heart failure. Whether a child presented with pre-ECMO
cardiac arrest or received extracorporeal cardiopulmonary resuscitation
support was recorded.
Complications reported during ECMO included 8 standardized sys-
tem complications as defined by ELSO: (1) mechanical, requiring a
change of equipment or intervention (oxygenator failure, raceway
rupture, other tubing rupture, pump malfunction, heat exchange mal-
function, clots in the oxygenator, bridge, bladder, or hemofilter, air in
circuit, cracks in connectors, cannula problems); (2) hemorrhagic,
requiring transfusion or other intervention (gastrointestinal hemorrhage,
cannulation site bleeding, surgical site bleeding, hemolysis [plasma he-
moglobin > 50 mg/dL], disseminated intravascular coagulation); (3)
neurologic (clinical brain death, clinical seizures, electroencephalo-
graphic seizures, infarction, and hemorrhage confirmed by ultrasonog-
raphy or computed tomography); (4) renal (elevated creatinine,
hemodialysis, hemofiltration); (5) pulmonary (pneumothorax, pulmo-
nary hemorrhage); (6) infectious (culture-proven new infection, white
blood cell count < 1500/dL); (7) metabolic (glucose < 40 mg/dL,
glucose> 240 mg/dL, pH< 7.20, pH> 7.60, hyperbilirubinemia [>2
mg/dL direct,>13 mg/dL indirect, or>15 mg/dL total]); and (8) car-
diac (myocardial stun, cardiopulmonary resuscitation during ECMO,
cardiac arrhythmia, tamponade with blood, serous, or air). We also
determined the total number of system complications per child and
evaluated its association with survival.The Journal of Thoracic and CaCardiac transplantation as an event was determined using the re-
ported International Classification of Diseases, version 9, Current Pro-
cedural Terminology, or ELSO codes entered into the ELSO database.
The timing of ECMO in relationship to cardiac transplantation was
determined using 2 factors: (1) a transplant-associated ELSO proce-
dural code and (2) whether ECMO was used as a bridge to transplan-
tation. Children who had a transplant-associated ELSO procedural
code and had corresponding procedural timing of either during or after
extracorporeal life support were deemed to have received cardiac trans-
plantation after ECMO (post-ECMO cardiac transplantation). Addition-
ally, children who were listed for ECMO as a bridge to transplantation
and also had a transplant-associated code (International Classification
of Diseases, version 9, Current Procedural Terminology, or ELSO
code) were determined to have received post-ECMO cardiac
transplantation.
The primary outcome variable was survival to hospital discharge.
Statistical Analysis
Data were summarized using descriptive statistics, including percent-
ages for categorical variables and the mean  standard deviation and me-
dian and range for continuous variables. Univariate and multivariate
analyses were performed to determine the predictors of survival to hospital
discharge. The duration of ECMO and survival was determined separately
for the following subgroups: (1) congenital heart disease, which was further
divided into 1- and 2-ventricle physiology, (2) cardiomyopathy, and (3)
myocarditis. Univariate analyses were performed using the Student t test,
Fisher exact test, and chi-square test. Multivariate logistic regression anal-
ysis was performed to identify significant risk factors associated with sur-
vival. On logistic regression analysis, we included gender, race, weight,
age, duration of ECMO in days, diagnoses, and complications as potential
risk factors. Backward selection was performed to remove nonsignificant
risk factors. We have reported the regression coefficient (b) and odds ratios
for significant risk factors remaining in the final logistic regression model.
The tests were deemed significant at the 95% confidence level (P<.05).
Statistical Analysis Systems, version 9.2 (SAS Institute, Cary, NC), was
used for the analyses.RESULTS
During the 12-year study period, the ELSO registry
included 10,293 cardiac runs in children aged<18 years
reported by 154 centers, with an overall survival of
45%. This same period included 784 prolonged cardiac
ECMO runs in 777 children, constituting only 7.6% of
all cardiac ECMO runs. Seven children received 2 pro-
longed cardiac ECMO runs each; we included only the
first run data for analysis. The number of cardiac ECMO
and prolonged cardiac ECMO runs annually is shown in
Figure 1. The demographic information is listed in
Table 1.ECMO Duration
We grouped the ECMO support duration into 3 cate-
gories: 14 to 20.9, 21 to 27.9, and 28 days. Survival was
25% (120 of 475) in the group receiving ECMO for 14 to
20.9 days and 23% (39 of 167) in the group receiving
ECMO for 21 to 27.9 days. No difference was found in sur-
vival between these 2 groups. Those requiring ECMO for
28 days had an additional decrease in survival to 13%
(17 of 135; P< .01; Figure 2). No significant differencerdiovascular Surgery c Volume 148, Number 2 583
FIGURE 1. Total number of prolonged cardiac and cardiac extracorporeal membrane oxygenation (ECMO) runs from January 1, 2000 to December 31,
2011. Listed in parentheses are the number of centers that reported to the Extracorporeal Life Support Organization each year.
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era effect).Diagnosis
The diagnostic categories were as follows: congenital
heart disease (72%), cardiomyopathy (14%), myocarditis
(8%), and other (6%).Of thosewith congenital heart disease,
38% had 1-ventricle physiology, 60% had 2-ventricle phys-
iology, and in 2%, it was indeterminate. Survivalwas best for
the subgroup withmyocarditis (52%) followed by thosewith
cardiomyopathy (42%), and was worst for those with
congenital heart disease (15%; P< .01). Of the patients
with congenital heart disease, those with 2-ventricle physi-
ology had better survival than those with 1-ventricle physi-
ology (18% vs 10%; P ¼ .01; Table 2). Figure 3 shows the
differences in survival among the diagnostic groups over
time. The median survival time was 20.5 days for
1-ventricle physiology, 20.9 days for 2-ventricle physiology,
and 33.9 days for cardiomyopathy.More than one half (52%)
of the childrenwith a diagnosis ofmyocarditis survived; thus,
amedian survival time could not be calculated. Childrenwith
myocarditis (median age, 0.72 year) and cardiomyopathy
(median age, 1.7 years) were older than those with
1-ventricle physiology (median age, 0.05 year) and
2-ventricle physiology (median age, 0.10 year; P< .01).TABLE 1. Demographic information stratified by survival
Variable Entire cohort Survivors Nonsurvivors
Children (n) 777 176 (23) 601 (77)
Male gender (%) 55 52 56
White race (%) 58 59 58
Weight (kg)
Median 4.0 7.0* 4.0
Range 1.4-100 2-90 1.4-100
Age (y)
Median 0.17 0.64* 0.10
Range 0-18 0-18 0-18
Data in parentheses are percentages. *Significant difference in survival on univariate
analysis (P<.01).
584 The Journal of Thoracic and Cardiovascular SurgNo significant difference was found in age between those
with myocarditis and cardiomyopathy or between those
with 1-ventricle and 2-ventricle physiology.
Univariate Analysis
Older children and children weighing more at the initia-
tion of ECMO were more likely to survive to hospital
discharge (P< .01; Table 1). ECMO duration correlated
inversely with survival (P< .01; Figure 2). Gender, race,
support type (extracorporeal cardiopulmonary resuscitation
vs nonextracorporeal cardiopulmonary resuscitation), and
pre-ECMO arrest did not predict survival (Tables 1 and
2). Children with a fewer number of system complications
had better survival (P < .01). Renal, hemorrhagic,
metabolic, neurologic, pulmonary, mechanical, and
infectious complications were associated with poor
survival (Table 3).FIGURE 2. Survival stratified by extracorporeal membrane oxygenation
(ECMO) duration. Children receiving prolonged cardiac ECMO support
were divided into 3 groups according to the duration: 14 to 20.9, 21 to
27.9, and28 days. Dashed line represents the survival for overall cardiac
ECMO (45%). A significant decrease was seen in survival in all 3 pro-
longed ECMO duration subgroups compared with the overall cardiac
ECMO survival (P< .01). Survival decreased further to 13% after 28
days of ECMO support (P<.01).
ery c August 2014
TABLE 2. Underlying diagnosis determined from ICD, CPT, and
ELSO codes
ECMO indications
Entire cohort
(n)
Survivors
(n)
Nonsurvivors
(n)
Congenital heart disease 556 83 (15) 473 (85)*
1-Ventricle physiology 212 21 (10) 191 (90)*
2-Ventricle physiology 333 60 (18) 273 (82)*
Indeterminate physiology 11 2 (18) 9 (82)
Cardiomyopathy 108 45 (42)y 63 (58)
Myocarditis 61 32 (52)y 29 (48)
Other (shock, pulmonary
hypertension, heart failure)
52 16 (31) 36 (69)
Pre-ECMO arrest 290 73 (25) 217 (75)
ECPR 138 27 (20) 111 (80)
Data in parentheses are percentages. ICD, International Classification of Diseases;
CPT, Common Procedural Terminology; ELSO, Extracorporeal Life Support Organi-
zation; ECMO, extracorporeal membrane oxygenation; ECPR, extracorporeal cardio-
pulmonary resuscitation. *Poorer survival on univariate analysis. yBetter survival on
univariate analysis (P<.05).
TABLE 3. Complications during prolonged cardiac ECMO
Complications Entire cohort Survivors Nonsurvivors
System complications (n) 3.4  1.7 2.8  1.7* 3.6  1.6
Complication
Mechanical 531 106 (20) 425 (80)y
Cardiovascular 303 70 (23) 233 (77)
Hemorrhagic 498 92 (18) 406 (82)y
Renal 517 90 (17) 427 (83)y
Pulmonary 162 27 (17) 135 (83)y
Metabolic 251 37 (15) 214 (85)y
Neurologic 185 27 (15) 158 (85)y
Infectious 217 39 (18) 178 (82)y
Data presented as mean standard deviation or n (%). ECMO, Extracorporeal mem-
brane oxygenation. *Significantly different between survivors and nonsurvivors
(P<.01). yPoorer survival on univariate analysis (P<.05).
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The diagnosis of cardiomyopathy or myocarditis and
greater weight at ECMO initiation were independent pre-
dictors of survival after prolonged cardiac ECMO support.
Fewer days of ECMO and the lack of renal, neurologic,
and metabolic complications also improved survival
(Table 4).
Multivariate analysis was also performed on the data
from the nontransplanted children separately. This revealed
that the diagnosis of cardiomyopathy and myocarditis,
fewer days of ECMO, and the lack of renal complications
predicted improved survival. Weight and neurologic and
metabolic complications were no longer predictors of
survival.FIGURE 3. Survival stratified by diagnosis over time. The number of
children surviving with extracorporeal membrane oxygenation (ECMO)
support over time within the 4 major diagnoses: myocarditis, cardiomyop-
athy, and congenital heart disease (2-ventricle and 1-ventricle physiology).
A diagnosis of congenital heart disease, especially 1-ventricle physiology,
was a predictor of poor survival.
The Journal of Thoracic and CaBridge to Transplantation
A total of 140 children were listed as ‘‘bridge to trans-
plantation.’’ Of these, 44 underwent transplantation, and
70% survived (31 of 44). The children who were listed as
using ECMO as a ‘‘bridge to transplantation’’ were older
(median age, 1.1 vs 0.11 year; P<.01) and more likely to
have a noncongenital diagnosis (51% vs 23%, P< .01)
than children without a listing of ‘‘bridge to
transplantation.’’
Cardiac Transplantation
Of the 777 children, 86 (11%) were reported as having
received cardiac transplantation. Of these 86 children, 7%
(56 of 777) had undergone cardiac transplantation after pro-
longed ECMO support (post-ECMO cardiac transplanta-
tion); 3 of these children had undergone combined heart
and lung transplantation. The remaining 30 children were
listed as having received cardiac transplantation, but
whether they had required ECMO before or after cardiac
transplantation could not be determined from the reported
data. Therefore, we did not include these children in
the post-ECMO cardiac transplantation analysis. Of the
56 children who had undergone post-ECMO cardiacTABLE 4. Multivariate analysis for predictors of survival (all
children)
Variable b estimate P value
OR for
survival
(95% CI)
Intercept 0.74  0.34 .03
Myocarditis vs congenital 1.54  0.31 <.01 4.7 (2.5-8.7)
Cardiomyopathy vs congenital 1.11  0.26 <.01 3.0 (1.8-5.0)
Weight (per 1-kg increase) 0.02  0.01 <.01 1.02 (1.01-1.03)
Days of ECMO (per 1-d
increase)
0.06  0.02 <.01 0.94 (0.91-0.97)
Renal complications 0.40  0.10 <.01 0.45 (0.30-0.67)
Neurologic complications 0.28  0.13 .03 0.57 (0.34-0.95)
Metabolic complications 0.24  0.11 .03 0.63 (0.40-0.98)
OR, Odds ratio; CI, confidence interval; ECMO, extracorporeal membrane
oxygenation.
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FIGURE 4. Competing outcomes analysis showing outcomes as follows: children who died without receiving cardiac transplantation, children who sur-
vived to hospital dischargewithout receiving cardiac transplantation, children who survived to discharge after receiving cardiac transplantation, and children
who died after cardiac transplantation. As the duration of prolonged ECMO increased, the most prominent outcome was death without undergoing trans-
plantation. The transplanted population constituted only a small percentage of the cohort. ECMO, Extracorporeal membrane oxygenation.
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the nontransplanted children (P<.01). Children who had
received post-ECMO cardiac transplantation were older
(median age, 1.8 vs 0.14 year; P<.01) and more likely to
have a noncongenital diagnosis (59% vs 24%, P< .01)
than children who did not receive post-ECMO cardiac
transplantation. The potential outcomes after prolonged
ECMO support have been detailed in a competing outcomes
graph (Figure 4). Within the nontransplanted population,
the children requiring prolonged ECMO for the diagnosis
of myocarditis had 50% survival.
ECMO for 28 Days
A total of 135 children received prolonged cardiac
ECMO for 28 days. Among these, 13% (17/135) sur-
vived. One hundred fourteen of these children had not
received cardiac transplantation and in this cohort only
7% (8/114) survived. Children without congenital heart dis-
ease had better survival (noncongenital diagnosis 25% vs
congenital 7%; P< .01), with no difference in survival
noted by the type of congenital diagnosis. Similar to the
entire cohort, younger age and lower weight were predictors
of poor survival in this subgroup. No significant difference
was found in survival between children with a diagnosis of
myocarditis who required ECMO for 14 to 27.9 days versus
28 days (56% vs 33%, P ¼ .29).
DISCUSSION
The present study is the largest outcomes analysis of pro-
longed cardiac ECMO in children reported to date. The pri-
mary finding of our study was that the survival of children
requiring prolonged cardiac ECMO, defined as an586 The Journal of Thoracic and Cardiovascular SurguninterruptedECMOduration of14 days, was significantly
lower compared with the overall pediatric cardiac ECMO
survival during the same period. The findings of poor sur-
vival, especially for smaller children with underlying
congenital heart disease, will be helpful for decision making
and parental counseling. Cardiac transplantation in this
cohort was achieved rarely and was associated with high
mortality compared with the current benchmarks for cardiac
transplantation survival. Single-center outcomes will be less
generalizable owing to the small numbers and variations in
clinical practice among centers. Using an international data-
base such asELSOallows for a better estimate of outcomes in
instances such as pediatric prolonged cardiac ECMO, which
occurs with a low frequency in individual institutions.
The survival in our cohort was 23% compared with 45%
in the overall pediatric cardiac ECMO runs during the same
period. Survival decreased further to 13%when the support
duration was 28 days. Although a lower body weight at
ECMOwas associated with decreased survival on multivar-
iate analysis, it was no longer an independent predictor of
survival when the transplanted population was removed.
This indicates possible collinearity between cardiac trans-
plantation and weight at ECMO, with larger and older chil-
dren having an increased likelihood of undergoing cardiac
transplantation. Those with a congenital diagnosis had
poorer survival; this corresponds with previous data
analyzing ECMO survival by diagnosis.11
Our data have demonstrated that using prolonged cardiac
ECMO as a bridge to recovery is not ideal. When studying
children not receiving cardiac transplantation, only 19%
survived; with a support duration of 28 days, the survival
decreased further to 7%. Thus, very few children notery c August 2014
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myocardial recovery with prolonged ECMO support. An
exception to this was the subgroup with myocarditis, which
showed 50% survival with prolonged cardiac ECMO sup-
port used as a bridge to recovery.
Children receiving prolonged cardiac ECMO rarely
reached cardiac transplantation. Older children, who were
more likely to have myocarditis or cardiomyopathy than
congenital heart disease, were also more likely to be listed
as ‘‘bridge to transplantation’’ and to have undergone post-
ECMO cardiac transplantation. The greater number of older
children who were bridged to transplantation and/or under-
went transplantation might be a reflection of the longer wait
times for infants than for older children and a resulting hes-
itancy to list infants for transplantation.
Previous studies have been mixed when determining the
outcomes of children who underwent transplantation after
ECMO support. One single-center study reported no differ-
ence in long-term survival with cardiac transplantation after
ECMO compared with those undergoing cardiac transplan-
tation without previous ECMO support.12 In contrast, in
another study, post-ECMO cardiac transplantation was
associated with poor survival.11 In our cohort, those under-
going cardiac transplantation after prolonged ECMO had a
66% survival rate to hospital discharge, which is poor
compared with the current benchmarks for survival after
cardiac transplantation provided by the International Soci-
ety of Heart and Lung Transplantation (85% to 94% at 1
year and 70% to 90% at 3 years).13 Another study of chil-
dren receiving ECMO as a bridge to transplantation found
that the median ECMO support duration for children who
died on the wait list was 10.4 days.11 Because the current
median wait time for cardiac transplantation is at least
several weeks, our outcomes data provide additional proof
that prolonged cardiac ECMO is a feasibly suboptimal strat-
egy for a bridge to cardiac transplantation.
The long-term outcomes after prolonged cardiac ECMO
are unknown; however, ECMO in and of itself has been re-
ported to be associated with poor long-term neurologic out-
comes.14,15 When considering the long-term outcomes in
the post-ECMO cardiac transplant group, having received
ECMO was reportedly a risk factor for a poor outcome at
1 year and that risk persisted even at 10 years.16 Studies
are necessary to determine the long-term outcomes of chil-
dren receiving prolonged cardiac ECMO as a bridge to re-
covery and as a bridge to transplantation.
Although VAD usage has been incorporated into the
management of adult cardiac insufficiency, the use of
VAD in the pediatric setting is not as prevalent, especially
in the United States. Recent reports from prospective trials
involving pediatric VADs have reported 88% to 92% sur-
vival.17 A study using the United Network for Organ
Sharing database showed that children who received VAD
support had better 5- and 10-year post-transplantationThe Journal of Thoracic and Casurvival than those receiving ECMO.18 VAD as a support
strategy for children needing extended support for cardiac
insufficiency should be investigated further, because our
data indicate that ECMO is a poor tool for extended cardiac
support.
The major limitation of the present study was its retro-
spective nature and the inherent negative effects of selection
bias andmissing data. The information reportedwas at times
incomplete, and we were unable to verify the information
with the participating institutions. Also, despite standard-
ized definitions, participation from different institutions
can result in deviations in the classification and reporting
of data. Center-specific information regarding ECMO vol-
umes and the availability of VAD or transplantation was
unavailable; hence, we were unable to analyze the center-
based volumes or the use of ECMO as a bridge to VAD.
However, the use of a large international database allowed
for evaluation of a much larger population than possible
with single-center reports, making the results more general-
izable. Finally, within the ELSO database, we were able to
elucidate only survival to hospital discharge, which might
not translate into long-term or intact survival.
In conclusion, prolonged cardiac ECMO support (sup-
port duration  14 days) in children was associated with
poor survival to hospital discharge. Also, the cardiac
transplant-associated survival in this cohort was poor
(66%) compared with the current benchmarks (85%-
94% at 1 year and 70%-90% at 3 years). Thus, consider-
able attrition of donor hearts occurs when used in children
who have required prolonged cardiac ECMO. Therefore,
we believe that children should be transitioned to more
viable types of cardiac support such as VAD within the first
few days of ECMO support. Plans toward transition would
need to be made once attempts at weaning from ECMO
have been unsuccessful and within the first few days of
ECMO initiation. We acknowledge that survival after pro-
longed cardiac ECMO will be possible in a number of chil-
dren with noncongenital diagnoses. However, we would not
recommend that these children be maintained on prolonged
cardiac ECMO because the number of system complica-
tions will increase with time. It is important for institutions
that cannot offer VAD support to consider transferring chil-
dren requiring ECMO to other facilities for initiation of
VAD support in a timely manner.
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